Your Source for Venture Capital and Private Equity Financings

Elucid Pulls In $80M Series C

2023-11-09
BOSTON, MA, Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has raised $80 million in Series C funding.
The round was led by Elevage Medical Technologies, with additional participation from industry strategics and existing investors. With this funding, Elucid is poised to capitalize on the past year's momentum and expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease. This round brings the company's total funding to $121 million since inception.

Elucid is a medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software is designed to understand the root cause of cardiovascular disease deeply. PlaqueIQ powers Elucid's plaque analysis software, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue annotations by renowned pathologists. Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to measure coronary blockages non-invasively and the extent of ischemia. PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid plaque analysis software is available for commercial use in the U.S., UK, EU, and South Korea.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors